Celldex Therapeutics Inc

Latest Results (12.10.2025):

Celldex Therapeutics Inc reported its financial results for the second quarter of 2025, highlighting a strategic focus on research and development alongside a decrease in revenue compared to the previous year. The company continues to advance its clinical pipeline while managing its financial resources effectively.

Cash Position

As of June 30, 2025, Celldex held $630.3 million in cash, cash equivalents, and marketable securities, down from $673.3 million at the end of March 2025. The reduction was primarily due to operating activities, which used $44.0 million in the second quarter.

Revenues

Total revenue for the second quarter of 2025 was $0.7 million, and $1.4 million for the first half of the year, both decreases from $2.5 million and $2.7 million, respectively, in the same periods of 2024. The decline was mainly due to reduced services under manufacturing and research agreements with Rockefeller University.

Research and Development Expenses

R&D expenses increased to $54.2 million in Q2 2025 and $106.8 million for the first half of the year, up from $39.7 million and $71.3 million in 2024. This rise was driven by higher costs related to barzolvolimab clinical trials, contract manufacturing, and personnel expenses.

General and Administrative Expenses

G&A expenses rose to $10.4 million in Q2 2025 and $21.2 million for the six months ended June 30, 2025, compared to $9.1 million and $18.2 million in the previous year. The increase was attributed to higher stock-based compensation and an expanded employee headcount.

Net Loss

Celldex reported a net loss of $56.6 million, or ($0.85) per share, for the second quarter of 2025, and a net loss of $110.4 million, or ($1.66) per share, for the first half of the year. These figures are up from a net loss of $35.8 million and $68.7 million, respectively, in the comparable periods of 2024.

Financial Guidance

The company affirmed that its cash, cash equivalents, and marketable securities as of June 30, 2025, are sufficient to support its working capital needs and planned operations through 2027.